References
- Lipsky J. Mycophenolate mofetil. Lancet 1996; 348: 1357–9
- Liu V., Mackool B. T. Mycophenolate in dermatology. J Dermatol Treat 2003; 14: 203–11
- Budde K., Curtis J., Knoll G., Chan L., Neumayer H. H., Seifu Y., et al. Enteric‐coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1‐year study. Am J Transplant 2004; 4: 237–43
- Ikeda S., Imamura S., Hashimoto I., Morioka S., Sakuma M., Ogawa H. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res 2003; 295: S12–16
- Allison A. C., Eugui E. M. Purine metabolism and the immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77–84
- Nousari H. C., Sragovich A., Kimyai‐Asadi A., Orlinsky D., Anhalt G. J. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 265–8
- Mimouni M. D., Anhalt G. J., Cummins D. L., Kouba D. J., Thorne J. E., Nousari H. C. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003; 139: 739–42
- Salopek T. G., Logsetty S., Tredget E. E. Anti‐CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life‐threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47: 785–8
- Bredlich R. O., Grundmann‐Kollman M., Behrens S., Kerscher M., Peter R. U. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol 1999; 141: 934
- Grundmann‐Kollman M., Korting H. C., Behrens S., Kaskel P., Leiter U., Krahn G., et al. Mycophenolate mofetil: A new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40: 957–60
- Powell A. M., Albert S., Al Fares S., Harman K. E., Setterfield J., Bhogal B., et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 2003; 149: 138–45
- Grundmann‐Kollman M., Kaskel P., Leiter U., Krahn G., Behrens S., Peter R. U., et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999; 135: 724–5
- Megahed M., Schmiedeberg S., Becker J., Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid‐sparing agent. J Am Acad Dermatol 2001; 45: 256–9
- Ingen‐Housz‐Oro S., Prost‐Squarcioni C., Pascal F., Doan S., Brette M. D., Bachelez H., et al. Pemphigoide cicatricielle: Traitement par mycophénolate mofétil. Ann Dermatol Venereol 2005; 132: 13–16
- Schattenkirchner S., Eming S., Hunzelmann N., Krieg T., Smola H. Treatment of epidermolysis bullosa acquisita with mycophenolate mofetil and autologous keratinocyte grafting. Br J Dermatol 1999; 141: 932–3
- Trebing D., Ziemer A. Acquired epidermolysis bullosa with a highly varied clinical picture and successful treatment with mycophenolate mofetil. Hautarzt 2001; 52: 717–21
- Kowalzick L., Suckow S., Ziegler H., Waldmann T., Ponnighaus J. M., Glaser V. Mycophenolate mofetil in epidermolysis bullosa acquisita. Dermatology 2003; 207: 332–4